Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

33 results
Display

Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer

Zhu X, Lang J

Programmed death-1 (PD-1) and its ligand are part of the immune checkpoint pathway that down-regulates effector T cells in immune response, thereby causing immune suppression. The PD-1/programmed death-ligand 1 (PD-L1)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Angiographically Documented Macular Ischemia after Single Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion

Lee KH, Kang EC, Koh HJ

This report describes a case of angiographically documented foveal avascular zone (FAZ) enlargement after a single intravitreal injection of bevacizumab for macular edema secondary to central retinal vein occlusion (CRVO)....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection

Kim JM, Lee KW, Song GW, Jung BH, Lee HW, Yi NJ, Kwon CD, Hwang S, Suh KS, Joh JW, Lee SK, Lee SG

BACKGROUND/AIMS: The relationship between patient survival and biopsy-proven acute rejection (BPAR) in liver transplant recipients with hepatitis C remains unclear. The aims of this study were to compare the characteristics...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immune checkpoint blockade therapy for bladder cancer treatment

Kim J

Bladder cancer remains the most immunogenic and expensive malignant tumor in the United States today. As the 4th leading cause of death from cancer in United States, Immunotherapy blocking immune...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry

Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, Jo DY, Chung J, Sohn SK, Lee JW

Paroxysmal nocturnal hemoglobinuria (PNH) is a progressive, systemic, life-threatening disease, characterized by chronic uncontrolled complement activation. A retrospective analysis of 301 Korean PNH patients who had not received eculizumab was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study

Choi CH, Song ID, Kim YH, Koo JS, Kim YS, Kim JS, Kim N, Kim ES, Kim JH, Kim JW, Kim TO, Kim HS, Kim HJ, Park YS, Park DI, Park SJ, Song HJ, Shin SJ, Yang SK, Ye BD, Lee KM, Lee BI, Lee SY, Lee CK, Im JP, Jang BI, Jeon TJ, Cho YK, Chang SK, Jeon SR, Jung SA, Jeen YT, Cha JM, Han DS, Kim WH, IBD Study Group of the Korean Association for the Study of the Intestinal Diseases

PURPOSE: Infliximab is currently used for the treatment of active Crohn's disease (CD). We aimed to assess the efficacy and safety of infliximab therapy and to determine the predictors of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Changing Paradigm in the Management of Inflammatory Bowel Disease

Jang BI

Inflammatory bowel disease (IBD) is a chronic progressive idiopathic inflammatory disorder that involves the digestive tract from the mouth to the anus. Over the past decades, many therapeutic strategies have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Ideal Vaccination Strategy in Inflammatory Bowel Disease

Lee CK

Inflammatory bowel disease (IBD) is a long-standing disease that often requires long-term use of immunosuppressive agents including immunomodulators (such as azathioprine, 6-mercaptopurine and methotrexate) and tumor necrosis factor-alpha inhibitors (such...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation

Lee J, Kim BS, Park Y, Lee JG, Lim BJ, Jeong HJ, Kim YS, Huh KH

PURPOSE: Recently, bortezomib has been used to treat antibody-mediated rejection (AMR) refractory to conventional treatment such as plasmapheresis, intravenous immunoglobulin, and rituximab. The authors aimed to describe their experiences when...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Crohn's Disease Showing Favorable Response to Induction and Maintenance Therapy with Methotrexate after Failure of Anti-tumor Necrosis Factor Therapy

Choi J, Yun GW, Park YM, Kim JH, Youn YH, Park H, Park JJ

Thanks to the introduction of immumomodulators and biologics, therapeutic approaches in Crohn's disease have changed significantly during the past decade. Although new biologic therapy has dramatically improved the treatment of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current and Emerging Biologics for Ulcerative Colitis

Park SC, Jeen YT

Conventional medical treatment for ulcerative colitis can have limited efficacy or severe adverse reactions requiring additional treatment or colectomy. Hence, different biological agents that target specific immunological pathways are being...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Drug Survival Rates of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

Kang JH, Park DJ, Lee JW, Lee KE, Wen L, Kim TJ, Park YW, Lee SS

We investigated the compliance of Korean patients using tumor necrosis factor (TNF) inhibitors to treat rheumatoid arthritis (RA) and ankylosing spondylitis (AS), and identified potential predictors associated with treatment discontinuation....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease

Han SH, Mook-Jung

Alzheimer's disease (AD) is the most common form of dementia caused by neurodegenerative process and is tightly related to amyloid beta (Abeta) and neurofibrillary tangles. The lack of early diagnostic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cost-of-Illness and Quality of Life in Patients with Ankylosing Spondylitis at a Tertiary Hospital in Korea

Lee TJ, Park BH, Kim JW, Shin K, Lee EB, Song YW

The objectives of this study were to estimate the cost-of-illness (COI) and health-related quality of life (HRQOL) in patients with ankylosing spondylitis (AS) in Korea and to evaluate the effects...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Association between the Therapeutic Agent and the Compliance of the Patients with Inflammatory Bowel Diseases

Kang YS, Kim SY, Jo MH, Kang HW, Lee JK, Lim YJ, Koh MS, Lee JH, Yang CH, Kim JH

BACKGROUND/AIMS: Adherence of the patients with inflammatory bowel diseases is important to maintain the remission. However, the patients do not always keep their appointments for treatment. The aim of this...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Perspective: Role of Targeted Therapy in Colon Cancer

Chung HH, Jang BI

Colorectal cancer is the third most common malignant disease in incidence according to a report in 2009 from Korea. The 5-fluorouracil (5-FU) remains to be a major chemotherapeutic agents. But,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Patients with Arthritis Undergoing Surgery: How Should We Manage Tumour Necrosis Factor Blocking Agents Perioperatively?: A Systematic Literature Review

Pieringer , Danninger , Tzaribachev N, Bohler N, Pohanka E, Herold M

We systematically reviewed the literature on the infectious risk in patients treated with tumour necrosis factor blocking agents (TNF-BA) undergoing surgery: we searched the Medline (PubMed) and the online archive...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prospective Controlled Protocol for Three Months Steroid Withdrawal with Tacrolimus, Basiliximab, and Mycophenolate Mofetil in Renal Transplant Recipients

Oh CK, Kim SJ, Kim JH, Lee JH

During the past few years, new immunosuppressants, such as tacrolimus, mycophenolate mofetil (MMF) and basiliximab, have been shown to successfully decrease the incidence of acute rejection, possibly acting as potent...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Guidelines for the Management of Crohn's Disease

Ye BD, Yang SK, Shin SJ, Lee KM, Jang BI, Cheon JH, Choi CH, Kim YH, Lee H, IBD Study Group of the Korean Association for the Study of the Intestinal Diseases

Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) with uncertain etiopathogenesis. CD can involve any site of gastrointestinal tract from the mouth to anus and is associated with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Guidelines for the Management of Ulcerative Colitis

Choi CH, Kim YH, Kim YS, Ye BD, Lee KM, Lee BI, Jung SA, Kim WH, Lee H, IBD Study Group of the Korean Association for the Study of Intestinal Diseases

Ulcerative colitis (UC) is a chronic inflammatory bowel disorder characterized by a relapsing and remitting course. The quality of life can decreases significantly during exacerbations of the disease. The incidence...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr